- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02151812
Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR) (AGENT-ISR)
A Prospective Randomized Multicenter Non-inferiority Clinical Study to Determine the Safety and Performance of the Agent™ Paclitaxel-Coated PTCA Balloon Catheter (Hemoteq) Compared to the SeQuent® Please Paclitaxel-Releasing Coronary Balloon Catheter (B.Braun) for the Treatment of Coronary In-Stent Restenosis (AGENT-ISR)
The primary objective of this study is determine the safety and performance of the Agent™ Paclitaxel-Coated PTCA Balloon Catheter compared to the SeQuent® Please Paclitaxel-Releasing Coronary Balloon Catheter for the treatment of patients with narrowed previously-stented coronary arteries (in-stent restenosis).
The performance will be determined at six months post-procedure by quantitative coronary angiography (QCA) to measure Late Lumen Loss (LLL) in the re-opened stented segment. QCA results will be assessed by an independent, blinded angiographic core lab.
Study statistical hypothesis: The loss of in-stent luminal diameter at six months after treatment of the restenosed stent with the Agent™ study device is not larger than the respective LLL after treatment with the SeQuent® Please control devices, i.e. study device is non-inferior to the control device with respect to LLL.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lyon, France, 69007
- Centre Hospitalier Saint Joseph Saint Luc de Lyon
-
Montpellier, France, 34000
- Clinique du Millénaire, Montpellier
-
Montpellier, France, 34090
- CHU Montpellier, Hôpital Arnaud de Villeneuve
-
Nantes, France, 44093
- CHU de Nantes, Hôpital Laennec
-
Rouen, France, 76000
- Clinique Saint Hilaire, Rouen
-
-
-
-
-
Bad Nauheim, Germany, 61231
- Kerckhoff-Klinik
-
Berlin, Germany, 13353
- Charite Universitaetsmedizin Berlin
-
Düsseldorf, Germany, 40225
- Universitätsklinikum Düsseldorf
-
Giessen, Germany, 35392
- University Giessen
-
Reutlingen, Germany, 72764
- Klinikum am Steinenberg
-
Rostock, Germany, 18057
- Universitaetsklinikum Rostock
-
Ulm, Germany, 89081
- Universitaetsklinikum Ulm
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject must be at least 18 years of age
- Subject is willing and able to provide informed consent
- Subject is eligible for percutaneous coronary intervention
- Subject is willing to comply with all protocol-required follow-up evaluations
- Women of child-bearing potential must agree to use a reliable method of contraception
- In-stent restenosis in a lesion previously treated with either a drug-eluting or bare metal stent, located in a native coronary artery with a reference vessel diameter ≥ 2.0 mm and ≤ 3.5 mm
- Target lesion length must be ≤ 28 mm (by visual estimate) and must be covered by only one balloon
- Target lesion must have visually estimated stenosis ≥ 70% and < 100% in asymptomatic patients
- Target lesion must have visually estimated stenosis ≥ 50% and < 100% in symptomatic patients
- Thrombolysis in Myocardial Infarction (TIMI) grade flow in the target lesion must be ≥ 1
- Target lesion must be successfully pre-dilated.
Exclusion Criteria:
- Patient has life expectancy of less than 24 months
- Patient with known coronary artery spasm
- Patient with unprotected left main coronary artery disease
- Patient has current problems with substance abuse
- Patient has planned procedure that may cause non-compliance with the protocol or confound data interpretation
- Patient is participating in another investigational drug or device clinical study that has not reached its primary endpoint
- Patient intends to participate in another investigational drug or device clinical study within 12 months after the index procedure
- Woman who is pregnant or nursing
- Left ventricular ejection fraction < 25%
- Patient had PCI or other coronary interventions within the last 30 days
- Planned PCI or CABG after the index procedure
- Patient to receive other PCI interventions in the target vessel, such as rotablation, laser atherectomy, cutting balloon, DCB, DES, BMS, bioabsorbable scaffold etc.
- Patient to receive DCB in non-target coronary vessels
- Acute MI < 72h
- Cardiogenic shock
- Known allergies against Paclitaxel or other components of the used medical devices
- Known hypersensitivity or contraindication for contrast dye that cannot be adequately pre-medicated
- Intolerance to antiplatelet drugs, anticoagulants required for the procedure
- Platelet count < 100k/mm3 or > 500k/mm3
- Patient with renal failure with a serum creatinine of > 2.5mg/dL who is receiving dialysis or chronic immunosuppressant therapy
- Target lesion is located within a bifurcation involving a major side branch > 2 mm in diameter
- Target lesion is located within a saphenous vein graft or an arterial graft
- Target lesion with TIMI grade flow = 0 (total occlusion)
- Thrombus present in the target vessel
- > 50% stenosis of an additional lesion proximal or distal to the target lesion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Agent Paclitaxel-coated balloon
drug-coated balloon dilatation of the index lesion using a single Agent(TM) balloon that completely covers the restenotic lesion
|
After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
|
Active Comparator: SeQuent Please Paclitaxel-coated balloon
drug-coated balloon dilatation of the index lesion using a single SeQuent(R) Please balloon that completely covers the restenotic lesion
|
After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
in-stent late lumen loss
Time Frame: six months
|
In-stent late lumen loss (LLL) of the treated stented segment after PTCA using the Agent(TM) study device in comparison to the LLL after PTCA using the SeQuent(R) Please control device as measured by QCA at six months post-index procedure.
|
six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
technical success rate
Time Frame: during index procedure, less 1 hour
|
The ability to cross and dilate the lesion to achieve residual angiographic stenosis no greater than 30 percent
|
during index procedure, less 1 hour
|
clinical procedural success rate
Time Frame: within 24 hours of index procedure
|
Technical success with no composite of all death and MI noted within 24 hours of the index procedure.
|
within 24 hours of index procedure
|
In-stent percent diameter stenosis
Time Frame: 6 months post-index procedure
|
In-stent percent diameter reduction measured within the borders of the stent
|
6 months post-index procedure
|
In-segment percent diameter stenosis
Time Frame: 6 months post-index procedure
|
In-segment percent diameter reduction measured in the stented segment plus 5mm on either side.
|
6 months post-index procedure
|
In-stent binary restenosis rate
Time Frame: 6 months post-index procedure
|
In-stent binary restenosis is defined as ≥50% luminal narrowing within the borders of the stent observed at follow-up QCA.
|
6 months post-index procedure
|
In-segment binary restenosis rate
Time Frame: 6 months post-index procedure
|
In-segment binary restenosis is defined as ≥50% luminal narrowing in the stented segment plus 5mm on either side observed at follow-up QCA.
|
6 months post-index procedure
|
In-segment late lumen loss
Time Frame: 6 months post-index procedure
|
In-segment late lumen loss is the in-segment minimal lumen diameter (MLD) post index procedure minus the in-segment MLD at 6 months follow-up as determined by QCA.
|
6 months post-index procedure
|
In-stent minimal lumen diameter (MLD)
Time Frame: 6 months post-index procedure
|
In-stent MLD is measured within the borders of the stent.
|
6 months post-index procedure
|
In-segment minimal lumen diameter (MLD)
Time Frame: 6 months post-index procedure
|
In-segment MLD is measured in the stented segment plus 5mm on either side.
|
6 months post-index procedure
|
Target lesion revascularization (TLR) rate
Time Frame: pre-discharge, estim. <10 days
|
TLR rate during index in-hospital stay
|
pre-discharge, estim. <10 days
|
Target lesion revascularization (TLR) rate
Time Frame: 30 days
|
30 days
|
|
Target lesion revascularization (TLR) rate
Time Frame: six months
|
six months
|
|
Target lesion revascularization (TLR) rate
Time Frame: 12 months
|
12 months
|
|
Target lesion revascularization (TLR) rate
Time Frame: 24 months
|
24 months
|
|
Target lesion revascularization (TLR) rate
Time Frame: 36 months
|
36 months
|
|
Target vessel revascularization (TVR) rate
Time Frame: pre-discharge, estim. <10 days
|
TVR rate during index in-hospital stay
|
pre-discharge, estim. <10 days
|
Target vessel revascularization (TVR) rate
Time Frame: 30 days
|
30 days
|
|
Target vessel revascularization (TVR) rate
Time Frame: six months
|
six months
|
|
Target vessel revascularization (TVR) rate
Time Frame: 12 months
|
12 months
|
|
Target vessel revascularization (TVR) rate
Time Frame: 24 months
|
24 months
|
|
Target vessel revascularization (TVR) rate
Time Frame: 36 months
|
36 months
|
|
Cardiac, non-cardiac and all death rates
Time Frame: pre-discharge, estim. <10 days
|
rates during index in-hospital stay
|
pre-discharge, estim. <10 days
|
Cardiac, non-cardiac and all death rates
Time Frame: 30 days
|
30 days
|
|
Cardiac, non-cardiac and all death rates
Time Frame: six months
|
six months
|
|
Cardiac, non-cardiac and all death rates
Time Frame: 12 months
|
12 months
|
|
Cardiac, non-cardiac and all death rates
Time Frame: 24 months
|
24 months
|
|
Cardiac, non-cardiac and all death rates
Time Frame: 36 months
|
36 months
|
|
Myocardial infarction rates (by 3rd Universal Definition: all MI, QWMI, NQWMI)
Time Frame: pre-discharge, estim. <10 days
|
rates during index in-hospital stay
|
pre-discharge, estim. <10 days
|
Myocardial infarction rates (by 3rd Universal Definition: all MI, QWMI, NQWMI)
Time Frame: 30 days
|
30 days
|
|
Myocardial infarction rates (by 3rd Universal Definition: all MI, QWMI, NQWMI)
Time Frame: six months
|
six months
|
|
Myocardial infarction rates (by 3rd Universal Definition: all MI, QWMI, NQWMI)
Time Frame: 12 months
|
12 months
|
|
Myocardial infarction rates (by 3rd Universal Definition: all MI, QWMI, NQWMI)
Time Frame: 24 months
|
24 months
|
|
Myocardial infarction rates (by 3rd Universal Definition: all MI, QWMI, NQWMI)
Time Frame: 36 months
|
36 months
|
|
Stent thrombosis rate (by ARC definition)
Time Frame: pre-discharge, estim. <10 days
|
rates during index in-hospital stay
|
pre-discharge, estim. <10 days
|
Stent thrombosis rate (by ARC definition)
Time Frame: 30 days
|
30 days
|
|
Stent thrombosis rate (by ARC definition)
Time Frame: six months
|
six months
|
|
Stent thrombosis rate (by ARC definition)
Time Frame: 12 months
|
12 months
|
|
Stent thrombosis rate (by ARC definition)
Time Frame: 24 months
|
24 months
|
|
Stent thrombosis rate (by ARC definition)
Time Frame: 36 months
|
36 months
|
|
Target lesion failure (TLF) rate (composite of cardiac death, MI and TLR)
Time Frame: pre-discharge, estim. <10 days
|
rates during index in-hospital stay
|
pre-discharge, estim. <10 days
|
Target lesion failure (TLF) rate (composite of cardiac death, MI and TLR)
Time Frame: 30 days
|
30 days
|
|
Target lesion failure (TLF) rate (composite of cardiac death, MI and TLR)
Time Frame: six months
|
six months
|
|
Target lesion failure (TLF) rate (composite of cardiac death, MI and TLR)
Time Frame: 12 months
|
12 months
|
|
Target lesion failure (TLF) rate (composite of cardiac death, MI and TLR)
Time Frame: 24 months
|
24 months
|
|
Target lesion failure (TLF) rate (composite of cardiac death, MI and TLR)
Time Frame: 36 months
|
36 months
|
|
Target vessel failure (TVF) rate (composite of cardiac death, MI and TVR)
Time Frame: pre-discharge, estim. <10 days
|
rates during index in-hospital stay
|
pre-discharge, estim. <10 days
|
Target vessel failure (TVF) rate (composite of cardiac death, MI and TVR)
Time Frame: 30 days
|
30 days
|
|
Target vessel failure (TVF) rate (composite of cardiac death, MI and TVR)
Time Frame: six months
|
six months
|
|
Target vessel failure (TVF) rate (composite of cardiac death, MI and TVR)
Time Frame: 12 months
|
12 months
|
|
Target vessel failure (TVF) rate (composite of cardiac death, MI and TVR)
Time Frame: 24 months
|
24 months
|
|
Target vessel failure (TVF) rate (composite of cardiac death, MI and TVR)
Time Frame: 36 months
|
36 months
|
|
Change in Quality of Life
Time Frame: six months
|
Functional status of general health-related quality of life (QoL) measured by changes in SF-12 scores and EQ5D scores as compared to baseline
|
six months
|
Change in Quality of Life
Time Frame: 12 months
|
Functional status of general health-related quality of life (QoL) measured by changes in SF-12 scores and EQ5D scores as compared to baseline
|
12 months
|
Change in Quality of Life
Time Frame: 24 months
|
Functional status of general health-related quality of life (QoL) measured by changes in SF-12 scores and EQ5D scores as compared to baseline
|
24 months
|
Change in Quality of Life
Time Frame: 36 months
|
Functional status of general health-related quality of life (QoL) measured by changes in SF-12 scores and EQ5D scores as compared to baseline
|
36 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christian W. Hamm, MD, University Giessen, Germany
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arterial Occlusive Diseases
- Coronary Disease
- Coronary Stenosis
- Coronary Artery Disease
- Myocardial Ischemia
- Arteriosclerosis
- Atherosclerosis
- Coronary Restenosis
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Albumin-Bound Paclitaxel
Other Study ID Numbers
- HTQ002-Agent-ISR
- CIV-13-11-011728 (Other Identifier: EUDAMED)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on Agent Paclitaxel-coated balloon
-
Universitätsklinikum Hamburg-EppendorfBARMER; GermanVasc; MDEpiNet Verband Deutschland e.V.Not yet recruitingOutcome, Fatal | Paclitaxel Adverse Reaction
-
Singapore General HospitalRecruitingDialysis Access Malfunction | Neointimal HyperplasiaSingapore, Australia
-
C. R. BardCompletedIn-Stent RestenosisNetherlands, Belgium, Germany
-
Herz-Zentrums Bad KrozingenUniversity Heart Center Freiburg - Bad KrozingenWithdrawnPaclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-Restenosis (BAIR)In-stent Stenosis of Infrapopliteal ArteriesGermany
-
The People's Hospital of Liaoning ProvinceUnknownStable Angina Pectoris | Unstable Angina PectorisChina
-
C. R. BardCompletedCoronary Artery StenosisNetherlands
-
Beijing Anzhen HospitalUnknownOCT- Versus Angiography-guided Paclitaxel Drug-Coated Balloon Angioplasty in De Novo Coronary ArteryCoronary Artery DiseaseChina
-
Seung-Whan Lee, M.D., Ph.D.Active, not recruitingCatheterization, Peripheral | Popliteal Artery | Angioplasty, Balloon | Femoral ArteryKorea, Republic of
-
Ignacio J. Amat SantosCompleted
-
B. Braun Melsungen AGActive, not recruitingPeripheral Arterial Occlusive DiseaseGermany